Could a common diabetes drug protect heart and kidneys during hospital stays?

NCT ID NCT07273838

First seen Jan 06, 2026 · Last updated May 15, 2026 · Updated 18 times

Summary

This study tests whether adding an SGLT2 inhibitor (a type of diabetes medicine) to standard hospital care helps people with heart failure who also develop acute kidney injury. Researchers will compare outcomes like survival, need for dialysis, and symptom improvement between those who get the drug and those who get a placebo. About 130 adults hospitalized with worsening heart failure and kidney problems will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Yale New Haven Hospital

    RECRUITING

    New Haven, Connecticut, 06510, United States

    Contact

  • Yale New Haven Hospital-St. Raphael Campus

    RECRUITING

    New Haven, Connecticut, 06510, United States

    Contact

Conditions

Explore the condition pages connected to this study.